Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease
(NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important …

Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …

Background Hepatocellular carcinoma (HCC), the third most prevalent cause of cancer-
related death, is a frequent primary liver cancer with a high rate of morbidity and mortality. T …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …

Introduction The treatment landscape of hepatocellular carcinoma (HCC) has significantly
changed over the last 5 years with multiple options in the frontline, second line, and beyond …

Simple Summary Hepatocellular carcinoma (HCC) constitutes a major health burden,
accounting for> 80% of primary liver cancers globally. Inflammation has come into the …

JAK/STAT signaling pathway is one of the important regulatory signaling cascades for the
myriad of cellular processes initiated by various types of ligands such as growth factors …

Efficient hepatocellular carcinoma (HCC) treatment remains a significant challenge due to
the inherent limitations of traditional strategies. The exploration of polysaccharides' natural …

The tumor microenvironment has been recently reported to play a pivotal role in sustaining
tumor cells survival and protecting them from immunotherapy and chemotherapy-induced …